Is It Time To Buy Ultragenxy?
March 23, 2017 at 15:34 PM EDT
Nothing guts a drug stock like bad clinical trial data. Shares of Ultragenyx Pharmaceutical ( RARE ) fell as much as 10% after a seizure medication failed in a phase II study. Trading at a recent $72.22, the shares were down 7.7% after earlier falling as much as 10% to $70.51
